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Abstract
We have investigated EGF-driven signaling processes in rat intestinal epithelial cell lines that overexpress either the K5L1
integrin or the K2L1 integrin. Both cell types display efficient activation of Erk/MAP kinase, but only the K5L1 expressing
cells display a strong activation of Akt. A complex is formed between activated EGFR and K5L1, but not with K2L1; this
complex also contains ErbB3 and p85. Thus K5L1 can support efficient activation of both the Erk and the
phosphatidylinositol-3-kinase/Akt branches of the EGFR signaling cascade, whereas K2L1 can support only the Erk
branch. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
During the last few years, abundant evidence has
accumulated demonstrating that integrins and asso-
ciated cytoskeletal components play a key role in
permitting e⁄cient signal transduction through the
receptor tyrosine kinase (RTK)/Ras/MAP kinase
pathway [1,2]. Integrins can modulate the ability of
the pathway to respond to exogenous growth factors,
and can also directly stimulate elements of this sig-
naling cascade. Integrin regulation of the RTK/Ras/
MAP kinase pathway is known to occur at several
levels. Thus, there is good evidence that integrin en-
gagement can enhance the e⁄ciency of activation of
RTKs [3,4] and, in some cases, can even trigger RTK
activation in the absence of added growth factor [5].
In most cases, the integrin e¡ect on RTK activation
is accompanied by formation of a complex between
the RTK and the integrin [4,6]. Integrin engagement
can also in£uence e⁄ciency of signal transmission
between cytoplasmic components of the pathway
by regulating the activation of Raf-1 [7,8] or of
MEK [9].
The integrins are a complex family of heterodimer-
ic molecules comprised of at least 18 distinct K sub-
units and eight L subunits [10]. While not all K/L
heterodimers are permitted, there are about two doz-
en distinct integrins in vertebrates. This complexity
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engenders important questions concerning the possi-
bility of speci¢c roles for individual integrins in mod-
ulating signaling processes [11]. However, the e¡ects
of integrins on growth factor mediated activation of
the MAP kinase cascade seem rather promiscuous,
since a variety of integrin heterodimers are capable
of enhancing this process [12]. Nonetheless, there is
good evidence for unique roles in signaling and sub-
sequent biological e¡ects for some integrins. For ex-
ample, the K6L4 integrin demonstrates some selective
functions with respect to ErbB2 mediated signaling
and carcinoma cell invasion [13^15]. Similarly, spe-
ci¢c roles in regulating programmed cell death have
been suggested for the K6L1 integrin in breast epithe-
lial cells [16], and for the K5L1 integrin in several cell
types [17,18].
We have recently re-examined the role of the K5L1
integrin in protection against programmed cell death
[19]. Using a rat intestinal epithelial cell model, we
demonstrated that over-expression of K5L1, but not
of K2L1, provided dramatic protection against sev-
eral pro-apoptotic stimuli. Further, the protective ef-
fects of K5L1 were mediated through a phosphatidyl-
inositol-3-kinase (PI-3-kinase)/Akt dependent
pathway. Overexpression of K5L1 substantially en-
hanced the ability of growth factors to signal to
Akt [19], a kinase known to play an important role
in opposing apoptosis [20].
In the current report we explore the mechanistic
basis for enhanced signaling to Akt in rat intestinal
epithelial cells that overexpress K5L1. We show that
cells expressing either K5L1 or K2L1 are equally ca-
pable of activating the Erk/MAP kinase in response
to growth factors such as EGF, but only cells ex-
pressing K5L1 are able to e¡ectively activate Akt.
The K5L1 e¡ect primarily in£uences the maximal lev-
el of active Akt attained, rather than the concentra-
tion-response pro¢le for the growth factor. Enhanced
EGF-mediated activation of Akt in K5L1 cells is par-
alleled by increased autophosphorylation of EGF-re-
ceptor (EGFR, ErbB), and of ErbB3, and by in-
creased association of the p85 subunit of PI-3-
kinase with the ErbB family members. In addition,
a multi-protein complex is formed between activated
EGFR, ErbB3, p85 and K5L1, but not with K2L1.
Thus K5L1 seems capable of selectively regulating
the PI-3-kinase branch of the EGFR signaling path-
way.
2. Materials and methods
2.1. Cell culture and lysis
Human K2- or K5-expressing RIE-1 cells (lines K2-
P1 or K5-c10, respectively) were cultured as described
in a previous study [19]. Cells were harvested by
trypsinization, maintained in suspension for 45 min,
and then replated on ¢bronectin- or collagen I-
coated substrata for 1 h; EGF treatments at the
indicated concentrations were performed for the
last 5 min of the replating period. In some cases,
cells were pretreated with LY294002, PP1 or PP2,
or PD153035, which are selective inhibitors for PI-
3-kinase, Src-kinase, and EGFR kinase respectively.
Cell lysates for MAPK or PKB/Akt assays were pre-
pared in the same manner as previously described
[19]. Lysates for co-immunoprecipitations were pre-
pared as described in a previous study [5].
2.2. Western blots
Western blots for MAPK or PKB/Akt activities in
the lysates prepared from the cell lines were done
with either anti-active MAPK (Promega, Madison,
WI), anti-MAPK (Santa Cruz Biotech, Santa Cruz,
CA), anti-pS473 PKB/Akt (Upstate Biotechnology,
Lake Placid, NY), or sheep anti-rat PKB/Akt (New
England Biolabs, Beverly, MA) polyclonal antibod-
ies, as described previously [19]. Western blots for
expression levels of EGFR, ErbB3, p85, Grb2, or
L-tubulin in RIPA bu¡er lysates were performed
with rabbit polyclonal anti-EGFR antibody (a gift
from Dr. Shelton Earp, University of North Caroli-
na, Chapel Hill, NC), monoclonal anti-ErbB3 anti-
body (Upstate Biotechnology), rabbit polyclonal
anti-p85 antibody (Upstate Biotechnology), mono-
clonal anti-Grb2 antibody (Transduction Laborato-
ry, Lexington, KY), or monoclonal anti-L-tubulin
antibody (Boerhinger Mannheim, Germany), respec-
tively.
It should be noted that, under the conditions used
in most of the experiments reported here, ErbB fam-
ily members appear in Western blots as two bands,
both of which become tyrosine phosphorylated in
response to EGF. This doublet is due to the initial
trypsinization prior to replating the cells on collagen
I or ¢bronectin. Thus, when unperturbed monolayers
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are lysed and analyzed, the EGF receptor (and other
ErbB proteins) run as a single band corresponding to
the higher molecular mass component of the doublet
seen in the trypsinized cells (data not shown).
2.3. Immunoprecipitations
For EGFR or ErbB3 immunoprecipitation, lysates
with the same amount of protein in the same volume
were incubated overnight at 4‡C with sheep poly-
clonal anti-EGFR antibody, or monoclonal anti-
ErbB3 antibody (Upstate Biotechnology), and pro-
tein-G-Sepharose beads (Calbiochem, San Diego,
CA) were then added for a further 2 h. For co-im-
munoprecipitation of EGFR with integrin subunits,
lysates with equal amounts of protein in equal vol-
umes were immunoprecipitated with either anti-hu-
man K2 mAb (P1E6, Life Technologies, Rockville,
MD) or anti-human K5 monoclonal antibody
(MAB1996, Chemicon, Temecula, CA), by rolling
at 4‡C for 3 h. After addition of protein-G-Sephar-
ose beads, immunoprecipitates were further incu-
bated at 4‡C for 1.5 h. After washing once with
the cold lysis bu¡er and four times with ice-cold
PBS, the immunoprecipitates were suspended with
sodium dodecyl sulfate^polyacrylamide gel electro-
phoresis (SDS^PAGE) sample bu¡er and then boiled
for 5 min. The immunoprecipitates were blotted with
monoclonal anti-K5 antibody (Transduction Labora-
tory), rabbit polyclonal anti-K2 cytoplasmic tail anti-
body (a kind gift from Dr. G. Tarone, University of
Turin, Turin, Italy), rabbit polyclonal anti-EGFR
antibody, monoclonal anti-ErbB3 antibody, mono-
clonal anti-Grb2 antibody, rabbit polyclonal anti-
p85 antibody, or monoclonal anti-phosphotyrosine
antibody (clone 4G10, Upstate Biotechnology).
3. Results and discussion
In initial experiments we compared the ability of
the K5L1 and K2L1 integrins to support growth fac-
tor mediated activation of MAP kinase and of Akt.
Thus, RIE cells stably transfected with human K2 or
K5 subunits were allowed to attach to substrata
coated with the appropriate integrin ligands (collagen
and ¢bronectin, respectively). The cells were then
stimulated with various amounts of EGF, and the
activation of MAP kinase and Akt determined. As
seen in Fig. 1, both K5 cells and K2 cells displayed
robust activation of MAP kinase in response to
EGF; the maximal activities and the concentration
versus response pro¢les were very similar. By con-
trast, only K5 cells displayed a robust activation of
Akt. For both K5 cells and K2 cells, the maximal
achievable activation of Akt was usually attained
between 5 and 10 ng/ml of EGF; however, the max-
imal response attained in the K5 cells was approxi-
mately 4^5-fold greater than in the K2 cells. A similar
di¡erential response between K5 cells and K2 cells
was also seen after longer periods of treatment with
EGF; thus the result cannot be attributed to a de-
layed response (data not shown).
Receptor tyrosine kinases signal to multiple down-
stream e¡ectors via complex, branched pathways
[21,22]. The initiation of any one branch of the over-
all response often entails the binding of an SH2 do-
main adaptor protein to the activated, autophos-
phorylated RTK [23]. For the MAP kinase path,
Grb2 serves as a key adaptor, while for the PI-3-ki-
Fig. 1. EGF dose response for PKB/Akt and MAPK activation.
RIE K2-P1 or K5-c10 cells were replated on collagen I (20 Wg/
ml) or ¢bronectin (20 Wg/ml) for 1 h, respectively, and were
treated for the last 5 min with EGF at various concentrations
prior to harvest. In some cases, cells were pretreated with
LY294002 at 20 WM. The lysates were analyzed in Western
blots using anti-active MAPK, anti-MAPK, anti-phospho-PKB/
Akt (p-Ser473), or anti-PKB/Akt antibody. The band intensities
of PKB/Akt blots were quantitated by using a chemi£uores-
cence-based method (Amersham Pharmacia Biotech), as ex-
plained in a previous study [19]. The graph shows the ratio of
the band intensity of Ser473-phosphorylated PKB/Akt over that
of total PKB/Akt at the corresponding condition. The data
shown are representative of ¢ve independent experiments.
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nase/Akt branch the p85 subunit of PI-3-kinase is
essential. Thus, to further evaluate the ability of
K5L1 to selectively enhance growth factor signaling
to Akt, we examined the binding of Grb2 and of p85
to EGF receptor in both K5 cells and K2 cells.
Initially we examined the total cellular pools of the
various signaling components. Thus, as seen in Fig.
2A, there were comparable amounts of EGFR, Grb2
and p85 expressed in K5 cells and K2 cells. As seen in
Fig. 2B, however, there was enhanced autophosphor-
ylation of EGFR in K5 cells as compared to K2 cells,
as revealed by anti-phosphotyrosine Western blots.
This was accompanied by increased association of
p85 with the EGFR complex in K5 cells, as demon-
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strated by co-immunoprecipitation. By contrast, the
binding of Grb2 to the EGFR was similar in both
cell types. The selective inhibitor PD153035 dramat-
ically reduced EGFR autophosphorylation, and thus
p85 and Grb2 association, as expected. The di¡er-
ences in EGFR autophosphorylation and p85 re-
cruitment are more clearly revealed when EGF con-
centration^response pro¢les are examined. As seen in
Fig. 2C, in parallel to the Akt response of Fig. 1,
maximal attainable P85 association with EGFR was
reached at approximately 10 ng/ml of EGF; how-
ever, the maximal amount of p85 recruitment was
substantially greater in the K5 cells as compared to
the K2 cells. Thus in the K5 cells more phosphorylat-
ed EGFR and more p85 was found in the EGFR
immunocomplex. It has been suggested that binding
of p85 to EGFR can be increased subsequent to Src-
mediated tyrosine phosphorylation of the EGFR cy-
toplasmic domain [24]. However, treatment of K5
cells with the selective Src kinase inhibitors PP1 or
PP2 did not a¡ect association of p85 with EGFR
(Fig. 2D), suggesting that Src is not involved in
this system.
While the binding motifs for Grb2 on the EGFR
cytoplasmic domain have been well de¢ned, binding
sites for p85 are not obvious. Many of the complex
signaling properties of EGFR (ErbB) are thought to
occur via its heterodimerization with the other three
members of its family (ErbB2, 3, 4) [21,25]. It has
been suggested that PI-3-kinase activation in re-
sponse to EGF treatment takes place primarily via
heterodimerization of EGFR with ErbB3, which has
several p85 consensus binding sites, although it is not
an active kinase itself [26,27]. Thus, EGFR has Grb2
docking sites at positions 1068 and 1086 but no p85
binding sites, while ErbB3 has p85 sites at positions
1035, 1178, 1203, 1241, 1257, and 1270, but no Grb2
sites [28]. Another possibility is the adaptor protein
c-Cbl, which preferentially associates with EGFR
[29], and which provides a docking site for p85 [30].
To explore these issues, we examined the possibil-
ity of enhanced heterodimerization or activation of
ErbB3 in response to EGF. As seen in Fig. 3A,
Western blotting of cell lysates revealed that K2 cells
actually contained more ErbB3 than did the K5 cells.
In immunoprecipitates of total EGFR (Fig. 3A) the
amount of ErbB3 increased upon EGF treatment,
indicating preferential association of the activated
EGFR and ErbB3 receptors, as expected [21]. Fur-
ther, the amount of ErbB3 in the EGFR immuno-
complex was higher in the K5 cells than in K2 cells,
despite the fact that more ErbB3 is found in the K2
cells. We also examined the tyrosine phosphorylation
of ErbB3 and its association with p85. As seen in
Fig. 3B, there was signi¢cantly more tyrosine phos-
phorylation of ErbB3 and more associated p85 in the
ErbB3 immunoprecipitates from the K5 lysates as
compared to the K2 lysates. Thus there seems to be
enhanced formation of an EGFR/ErbB3/p85 com-
plex in the K5 cells in response to EGF. We also
tested for the presence of c-Cbl in the EGFR com-
plex. Treatment with EGF triggered increases in
c-Cbl association with the EGFR complex, but the
increase was similar in the K5 cells and K2 cells (data
not shown). Thus, enhanced binding of c-Cbl per se
does not explain the positive in£uence of K5L1 on PI-
3-kinase-dependent Akt activation.
We next explored the possibility of a selective as-
Fig. 2. Di¡erential formation of signaling complexes downstream of the EGFR in cells expressing di¡erent K integrin subunits. K2-P1
or K5-c10 cells were replated and treated with EGF at the indicated concentrations, in the same manner as described in Fig. 1. In
some cases, cells were pretreated with PD153035 at 10 WM. The data shown are representative of several experiments. (A) Expression
of signaling components. Total cell lysates prepared with RIPA bu¡er were Western blotted for EGFR, Grb2, p85, or tubulin.
(B) Di¡erential autophosphorylation of EGFR and signaling complex formation in K5-c10 cells. The lysates were immunoprecipitated
with anti-EGFR antibody and the immunoprecipitates were blotted for EGFR, phosphotyrosine, Grb2, or the p85 regulatory domain
of PI-3-K. After the proteins were transferred from a gel to a PVDF membrane, the membrane was cut into two pieces. The upper
part with higher molecular mass proteins was used for blotting for EGFR or phosphotyrosine, whereas the lower part was used for
blotting for p85 or Grb2. (C) EGF dose-dependent EGFR autophosphorylation and p85 association with EGFR. The lysates and
EGFR immunoprecipitates were prepared as described above. The upper parts (s 120 kDa) of gels (6% SDS^PAGE) were blotted for
EGFR or phosphotyrosine, whereas the lower parts (6 120 kDa) were blotted for p85. (D) Src does not a¡ect p85 association with
EGFR. Cells were treated with EGF and with the Src-selective inhibitors PP1 or PP2, or not. Immunoprecipitates of EGFR were an-
alyzed for total EGFR and for p85. The positions of molecular mass markers are shown with arrows. The experiments shown in this
¢gure were repeated at least twice.
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sociation between ErbB family members and the
K5L1 integrin. As seen in Fig. 4A, EGFR was co-
immunoprecipitated by anti-K5 antibody in K5 cells
treated with EGF, but not by anti-K2 antibody in K2
cells similarly treated. Exposure of cells to the EGFR
selective kinase inhibitor PD153035 blocked the abil-
ity of EGFR to co-immunoprecipitate with the K5L1
integrin. Reciprocal experiments precipitating with
anti-EGFR and then Western blotting for integrin
subunits con¢rmed the EGFR/K5L1 linkage (Fig.
4B). Thus, a fraction of activated EGFR was able
to selectively associate with the K5L1 integrin while
virtually no association with K2L1 was observed.
Similarly, as seen in Fig. 4C, the ErbB3 receptor
preferentially associated with K5L1 in the K5 cells
treated with EGF, despite the fact that more
ErbB3 is found in the K2 cells.
In summary, our results indicate that a fraction of
activated EGFR forms a complex with K5L1 integ-
rin, and that this complex also includes tyrosine
phosphorylated ErbB3. The ability of phosphorylat-
ed ErbB3 to bind the SH2 domain of p85 results in
enhanced recruitment of p85 to the EGFR complex.
The increased recruitment of p85 correlates well with
the higher levels of Akt activation seen in the K5
positive cells, and may thus substantially contribute
to the anti-apoptotic e¡ects of K5L1 overexpression
that we have previously observed [19]. By contrast,
Fig. 3. Heterodimerization of EGFR and ErbB3. (A) Co-immunoprecipitation of ErbB3 with EGFR. K2-P1 or K5-c10 cells were re-
plated on collagen or ¢bronectin respectively and treated with EGF as indicated. Cell lysates were Western blotted for total ErbB3
content. EGFR immunoprecipitates were Western blotted for EGFR and for ErbB3. (B) Co-immunoprecipitation of p85 with ErbB3.
The experimental conditions were similar to those of A except that anti-ErbB3 was used to form an immune complex, which was
then Western blotted for phosphotyrosine and for p85. The positions of molecular mass markers are shown with arrows. The data
shown are representative of at least three di¡erent experiments.
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the recruitment of Grb2 and activation of the Erk/
MAP kinase pathway is similar in both K5 cells and
K2 cells. It seems that the level of tyrosine phosphor-
ylation of EGFR attained in either cell type is su⁄-
cient to promote full activation of the Erk pathway.
However, full activation of the PI-3-kinase/Akt path-
way may require the enhanced recruitment and tyro-
sine phosphorylation of ErbB3 seen in the K5L1 cells.
Fig. 4. Co-immunoprecipitation of activated EGFR with K5, but not with K2, integrin subunit. The lysates and co-immunoprecipita-
tions with anti-human K2, K5, or EGFR were prepared as described in Section 2. In some cases cells were pretreated with PD153035
at 10 WM prior to being replated on substrates. (A) Co-immunoprecipitation of activated EGFR with anti-human K5 antibody. The
K5 and K2 immunoprecipitates were blotted for anti-EGFR, and then stripped prior to blotting with either human K2 or K5 subunit
antibody. (B) Reciprocal co-immunoprecipitation of human K5 integrin subunit with anti-EGFR antibody. The immunoprecipitates
using anti-EGFR were blotted for integrin subunits and then stripped prior to re-blotting with anti-EGFR antibody. (C) Co-immuno-
precipitation of K5 subunit with ErbB3. Lysates from EGF treated cells were immunoprecipitated with anti-ErbB3. The immune com-
plexes were Western blotted with anti-ErbB3, anti-K5 or anti-K2 antibodies. The positions of molecular mass markers are shown with
arrows. The experiments shown in this ¢gure were repeated at least twice.
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At this point it is not clear if K5L1 primarily in-
teracts with EGFR, with ErbB3, or with both pro-
teins. Similar selective association of a particular in-
tegrin with growth factor receptors has been
demonstrated previously for the case of KvL3 associ-
ating with PDGFR [6] and VEGFR [4]. For the
EGFR, previous work indicated that EGFR associ-
ates with L1 integrins [5], but the K subtype speci¢c-
ity had not been de¢ned. It should be noted that our
studies on the K5L1 integrin do not preclude the
possibility that other integrin K/L heterodimers may
also be e⁄cient in supporting PI-3-kinase/Akt signal-
ing. However, K2L1 clearly does not have this ability
to the same degree as K5L1; thus there seem to be
distinct sub-sets of L1 integrins in terms of RTK
activation and e¡ects on PI-3-kinase signaling. It
should be noted that other investigators have sug-
gested that the EGF-R can complex with K2L1 to
some degree; however, in this instance no direct
comparison with K5L1 was made [31]. Another study
has linked K5L1 protection against apoptosis to a
pathway that involves focal adhesion kinase
(FAK), Shc, PI-3-kinase, Akt and Bcl-2 [32]. This
study may be complementary to the present work
because of the possibility of interplay between
FAK signaling and RTK signaling.
The precise mechanism of the RTK/integrin asso-
ciation is still unclear. It is not known whether the
association is direct, or whether other proteins assist
in the formation of a complex between the integrin
and the RTK. It has been suggested recently [33] that
the cooperation between integrins and growth factor
receptors may be based on formation of a complex
between the adhesion-activated intracellular tyrosine
kinase FAK and the cytoplasmic domains of the re-
ceptor tyrosine kinases. However, another recent
study [34] has indicated that the association between
KvL3 and PDGF receptor or VEGFR2 is via the
external domain of L3, rather than the cytoplasmic
domain. Thus, the precise mechanism(s) of integrin/
RTK interaction remain somewhat controversial. In
the present case we have shown that the K5L1 integ-
rin is much more e¡ective than the K2L1 integrin in
supporting formation of an EGFR/ErbB3/P85 com-
plex in intestinal epithelial cells. These ¢ndings pro-
vide a basis for understanding the selective e¡ects of
K5L1 in supporting enhanced activation of the PI-3-
kinase/Akt signaling pathway and its role in inhibit-
ing apoptosis.
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